Investment Rating - The report suggests a positive outlook for domestic brands and a recovery for international beauty brands in the Chinese market, indicating potential investment opportunities in the cosmetics and medical beauty sectors [2][3]. Core Insights - The cosmetics and medical beauty sector underperformed the market, with the Shenwan Beauty Care Index declining by 3.3% from July 25 to August 1, 2025, while the Shenwan Cosmetics Index fell by 2.6% [3][4]. - Domestic brands showed strong growth during the off-season, with notable increases such as Han Shu up 58%, Proya up 23%, Marubi up 72%, and Kefu Mei up 28%, indicating resilience in the market [7][17]. - International beauty brands, represented by L'Oréal, are recovering in the Chinese market, with a 3% growth in Q2 2025, supported by promotional events like the 618 shopping festival [7][24]. - The report highlights the success of Lin Qingxuan, a high-end domestic skincare brand, which saw revenue grow from 690 million yuan in 2022 to 1.21 billion yuan in 2024, showcasing the potential of domestic brands [13][14]. Summary by Sections Industry Performance - The beauty and medical aesthetics sector has shown weaker performance compared to the overall market, with specific indices declining [3][4]. - The report notes that the cosmetics market is transitioning from quantity to quality, with a significant increase in e-commerce sales, which accounted for 47% of cosmetics sales in 2024, up from 22% in 2016 [9][30]. Key Company Highlights - L'Oréal's sales in China for H1 2025 reached approximately 186.19 billion yuan, with a 3% year-on-year increase, indicating a recovery in the Chinese market [24]. - Procter & Gamble reported a record net sales of approximately 604.95 billion yuan for the 2025 fiscal year, with the beauty segment achieving a net sales of approximately 107.66 billion yuan, reflecting a 2% growth [25]. - Lin Qingxuan's product matrix includes 188 SKUs, with a focus on high-quality natural ingredients, and it has established a strong supply chain and distribution network [14][16]. Market Trends - The report emphasizes the growing market for high-end skincare products, with the market size expected to increase from 749 billion yuan in 2019 to 1,144 billion yuan by 2024, indicating a compound annual growth rate (CAGR) of 13.8% [14][15]. - The domestic brands are gaining market share, with the top ten brands in the skincare market now evenly split between domestic and international brands, reflecting a shift in consumer preferences [30][31].

| 代码 | 简称 | 今日涨跌 | 今日换手 | 5日均线 | 10日均线 | 5日较10日均线 | 最新价 | 较10日均线乖 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | （%） | 率（%） | （元） | （元） | 距离（%） | （元） | 离率（%） | | 002052 | 同洲 | -0.77 | 2.45 | 10.71 | 10.85 | -1.25 | 10.32 | -4.85 | | | 电子 | | | | | | | | | 002989 | 中天 | -0.77 | 2.14 | 32.36 | 32.71 | -1.07 | 31.12 | -4.87 | | | 精装 | | | | | | | | | 603983 | 丸美 生物 | -2.64 | 0.70 | 39.79 | 40.17 | -0.93 | 38.69 | -3.68 | | | 格科 | | | | | | | | | 688728 | 微 | 0.46 | 0.48 | 15.71 | 15.82 | -0.68 ...

Market Overview - The Shanghai Composite Index is at 3555.41 points, with a decline of 0.50% [1] - The total trading volume of A-shares is 128.87 billion yuan [1] Technical Analysis - A total of 64 A-shares have seen their 5-day moving average cross below the 10-day moving average [1] - Notable stocks with significant distance between their 5-day and 10-day moving averages include: - Tongzhou Electronics: -1.29% - Marubi Biological: -0.95% - GeKao Micro: -0.69% [1] Individual Stock Performance - Key stock performances include: - Tongzhou Electronics (002052): Today's change -1.15%, 5-day MA at 10.70 yuan, 10-day MA at 10.84 yuan, with a distance of -1.29% [1] - Marubi Biological (603983): Today's change -2.84%, 5-day MA at 39.78 yuan, 10-day MA at 40.16 yuan, with a distance of -0.95% [1] - GeKao Micro (688728): Today's change 0.33%, 5-day MA at 15.71 yuan, 10-day MA at 15.82 yuan, with a distance of -0.69% [1] - Other notable stocks include: - Huatai Securities (601059): Today's change -0.86%, 5-day MA at 16.73 yuan, 10-day MA at 16.84 yuan, with a distance of -0.66% [1] - Jiabao (600622): Today's change -1.01%, 5-day MA at 3.08 yuan, 10-day MA at 3.10 yuan, with a distance of -0.64% [1] Additional Stock Movements - Other stocks with notable movements include: - Laka Laka (300773): Today's change -4.02%, 5-day MA at 27.62 yuan, 10-day MA at 27.73 yuan, with a distance of -0.39% [2] - Yongtai Technology (002326): Today's change 4.09%, 5-day MA at 13.25 yuan, 10-day MA at 13.29 yuan, with a distance of -0.32% [2] - Qijing (603677): Today's change -0.46%, 5-day MA at 19.91 yuan, 10-day MA at 19.96 yuan, with a distance of -0.25% [2]

Group 1 - The Shanghai Composite Index is at 3575.26 points with a slight increase of 0.06% and total A-share trading volume is 735.89 billion yuan [1] - A total of 55 A-shares have seen their 5-day moving average cross below the 10-day moving average, indicating potential bearish trends [1] - Notable stocks with significant distance between their 5-day and 10-day moving averages include Tongzhou Electronics at -1.19%, Marubi Biological at -0.82%, and Everbright Jiabao at -0.61% [1] Group 2 - Additional stocks showing a downward trend in their moving averages include Ge Ke at -0.61%, Hisense at -0.57%, and Beichen at -0.55% [1] - Other companies with notable moving average crossovers include Wan Shi at -0.53%, Baoling at -0.50%, and Zhejiang University at -0.49% [1] - The report also highlights stocks like PAI Neng and ST Zhong with minor declines in their moving averages, indicating a broader trend in the market [1]

Group 1 - The central government emphasizes boosting consumption and breaking the "involution" to promote domestic circulation and achieve economic goals for the year [1] - The focus on domestic demand policies is highlighted as a stable direction to counter external uncertainties, with significant results from consumption-boosting policies in the first half of the year [1] - The expansion of government subsidies for home appliances from 8 categories to 12, including 3C products, indicates a potential for further subsidy expansion in the second half of the year [1] Group 2 - The estimated consumption subsidies of 138 billion for "trade-in" programs are expected to increase retail sales growth by 1.3 percentage points in the second half of the year [1] - The overall retail sales growth is projected to moderate from 5% in the first half to 4.3% in the second half, with an annual growth rate of 4.6% [1] - Investment opportunities in the consumer sector for 2025 include domestic brands and high-growth emotional consumption sectors, as well as the burgeoning silver economy and AI+ consumption [2]

Group 1 - The stock price of Marubi Biotechnology closed at 40.04 yuan on July 30, 2025, down 0.15% from the previous trading day, with a trading volume of 0.87 billion yuan and a turnover rate of 0.54% [1] - Marubi Biotechnology operates in the beauty care industry, focusing on anti-aging eye products, with main brands "Marubi" and makeup brand "PL Love Fire" [1] - The company is transitioning towards the biotechnology sector by restructuring its collagen research and plans to expand into the medical beauty and healthcare industries [1] Group 2 - Marubi Biotechnology has commenced construction of a Class III medical device pilot base in Zhuhai International Health Port, focusing on the research and industrialization of recombinant collagen [1] - The company has set a ten-year research plan aiming to obtain a registration certificate for injectable recombinant collagen Class III medical devices by 2026 [1] - In 2024, the company plans to invest 73.54 million yuan in research and development, employing 94 research personnel [1] Group 3 - On July 30, 2025, the net outflow of main funds for Marubi Biotechnology was 12.24 million yuan, accounting for 0.08% of the circulating market value [2]

Core Viewpoint - Marubi Biological has officially started construction on a Class III medical device pilot base in Zhuhai, focusing on the research and industrialization of recombinant collagen protein in the medical beauty field, indicating a strategic shift from a cosmetics company to a biotechnology company [1][3]. Company Developments - The project aims to deepen research into recombinant collagen protein, expanding its application from cosmetic beauty to medical beauty, reflecting Marubi's ambition to enhance its competitive edge in the cosmetics industry and explore new revenue streams in the medical sector [1][3]. - Marubi has changed its name from "Marubi Co., Ltd." to "Marubi Biological" and has invested in medical biomaterials companies, signaling a commitment to this new direction [1][3]. Market Trends - The focus on recombinant collagen protein aligns with Marubi's historical emphasis on anti-aging products, particularly in eye care, and the growing popularity of this ingredient in the skincare market [3][4]. - The market for recombinant collagen protein is still in its early stages, presenting opportunities for early entrants like Marubi to capture market share [3][4]. Research and Development Strategy - Marubi plans to invest over 1 billion yuan in recombinant collagen protein research by 2032, with specific milestones including obtaining medical device registration by 2026 and advancing into serious medical applications by 2028 [4][5]. - Despite the ambitious R&D plans, Marubi's R&D expenses have not kept pace with revenue growth, leading to a decline in R&D expense ratios from 2.80% in 2023 to 2.48% in 2024 [5][9]. Financial Performance - Marubi's revenue has shown significant growth, surpassing 2.2 billion yuan in 2023, a 28.52% increase from the previous year, with projections indicating potential revenue exceeding 3 billion yuan by 2025 [7][9]. - The company has successfully adapted its marketing strategies, particularly through online channels and product focus, contributing to its revenue growth [7][8]. Competitive Landscape - Marubi faces challenges from increasing online marketing costs and rising sales expenses, which have impacted profitability, with net profit margins decreasing from 26.56% in 2020 to 11.52% in 2024 [9][10]. - The reliance on a single ingredient, recombinant collagen protein, poses risks, as market trends can shift rapidly, potentially affecting long-term sustainability [9][10].

Core Insights - The 2025 medical beauty industry is expected to show diverse development trends, with various segments demonstrating distinct characteristics [1][5] - Light medical beauty is becoming mainstream due to its minimal trauma, quick recovery, and low risk, attracting many first-time consumers [1][8] - The male medical beauty market is rapidly growing, with 73% of men planning to increase their spending in 2024, focusing on anti-aging and minor adjustments [1][23] - Cross-border medical beauty is booming, with South Korea and Hong Kong being the preferred destinations, accounting for 62% and 45% respectively [1][37] Group 1: Light Medical Beauty - Light medical beauty accounts for 44% in injection and 47% in phototherapy, with a projected compound annual growth rate (CAGR) of 20%-30% over the next five years [1][11] - The primary demographic for light medical beauty is women, making up 89% of the interest group, with 37.5% aged 25-29 [1][14] - Popular procedures include water light needles and photon rejuvenation, with compliance, safety, and efficacy being key consumer concerns [1][18] Group 2: Male Medical Beauty - The male medical beauty market is identified as the "second curve" of industry growth, with significant interest in anti-aging and minor adjustments [1][23] - Social media and workplace scenarios are major drivers for male consumers, with core concerns including nasolabial folds and tear troughs [1][29] - 43% of men plan to increase their medical beauty spending in 2024, indicating a shift in consumer behavior [1][25] Group 3: Cross-Border Medical Beauty - The demand for cross-border medical beauty is projected to reach 26% by 2025, with high cost-effectiveness and professionalism being the main attractions [1][37] - However, concerns about language barriers and difficulties in rights protection remain significant [1][37] Group 4: Youth and Medical Beauty - High school graduates are emerging as a significant consumer group during the summer, with a 245% increase in discussions around "post-exam medical beauty" [2][5] - Popular procedures among this demographic include double eyelid surgery and phototherapy, driven by aesthetic recognition and social media influence [2][5] Group 5: Cross-Industry Integration - Beauty and cosmetics companies are increasingly entering the medical beauty sector, with medical-grade dressings becoming popular entry products [2][5] - The medical device auxiliary market is expected to reach 25.38 billion yuan by 2026, with a CAGR of 30% [2][5]

证券之星消息，7月30日化妆品板块较上一交易日下跌0.14%，华业香料领跌。当日上证指数报收于 3615.72，上涨0.17%。深证成指报收于11203.03，下跌0.77%。化妆品板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 837023 | 芭薇股份 | 20.03 | 2.98% | 4.50万 | Ir 8942.13万 | | 600223 | 福瑞达 | 8.56 | 2.03% | 23.53万 | 2.00亿 | | 301371 | 敷尔佳 | 26.64 | 0.72% | 2.81万 | 7456.98万 | | 300849 | 锦盛新材 | 13.40 | 0.68% | 8.72万 | 1.17亿 | | 600315 | 上海家化 | 22.33 | 0.40% | 12.15万 | 2.72亿 | | 603630 | 拉芳家化 | 23.04 | 0.39% | 7.55万 | 1.74亿 | | 603605 | 班莱雅 | 83.85 ...

胶原蛋白赛道或将迎来竞争高峰期。 药企德展健康日前宣布，其重组Ⅲ型及XVII型人源化胶原蛋白已实现中试生产，并具备化妆品原料销 售能力。但在这项技术突破背后，横亘着医药级原料转化的巨大鸿沟——规模化生产线仍在建设中，真 正的产业化部署尚未完成。 事实上，在所有玩家头顶高悬的双重高压线并未松动：技术层面，医美级产品的规模化生产与质量控制 仍如绝壁矗立；准入层面，长达36个月的三类医疗器械审批周期与超千万元的单产品合规成本构筑着钢 铁闸门。 围绕重组胶原蛋白项目技术突破及申报节奏，21世纪经济报道以投资者身份致电德展健康。该公司工作 人员回复道："其技术路线与巨子生物等行业头部企业同属人源化胶原蛋白范畴，并无本质差别。当前 中试生产规模维持在500L水平，产品技术性能可满足护肤品、医美等商业化应用需求。" 但工作人员同时指出，由于尚未建立规模化量产能力，具体产业化路径仍需结合后续产能建设情况确 定。 德展健康产品结构显示，公司已布局重组胶原蛋白原料及其衍生产品体系。2024年，重组Ⅲ型人源化胶 原蛋白不仅实现原料销售，其创新的冻干海绵剂型产品也通过备案审批。 作为第三代胶原蛋白技术，该产品通过DNA重组技术构建三 ...